Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carpe is a line of over-the-counter (OTC) topical antiperspirant products specifically formulated for the management of hyperhidrosis (excessive sweating) in various body regions, including the hands, feet, and underarms. Developed by the company Carpe, these formulations primarily utilize aluminum sesquichlorohydrate as the active pharmacological agent. The mechanism of action involves the formation of temporary physical plugs within the eccrine sweat gland ducts; when the aluminum salts are applied, they dissolve in the sweat and then precipitate, creating a barrier that prevents sweat from reaching the skin surface. Carpe is frequently recommended as a non-invasive, first-line management strategy for patients with primary focal hyperhidrosis who require more efficacy than standard commercial antiperspirants but wish to avoid the irritation often associated with high-concentration aluminum chloride prescription treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Carpe.